Novo Nordisk Expands Wegovy Supply Amid Compounding Drug Concerns
The pharmaceutical giant faces challenges with counterfeit versions of its popular weight-loss medication, linked to multiple deaths and hospitalizations.
- Novo Nordisk has lifted restrictions on Wegovy prescriptions in the U.S., citing increased supply to meet rising demand.
- The company reported a 79% increase in Wegovy sales year-over-year, surpassing analysts' expectations and contributing to strong quarterly earnings.
- Concerns have emerged over compounded versions of semaglutide, associated with at least 10 deaths and 100 hospitalizations in the U.S.
- Novo Nordisk is collaborating with the FDA to address safety issues related to counterfeit and compounded drugs, which are not FDA-approved.
- Despite production challenges, Novo Nordisk continues to expand its market reach, with plans to launch Wegovy in India by 2026 amid high global demand.
The Times 
CNN 
Stat News 
Investor's Business Daily 
Investopedia 
Denver Gazette 
CNBC 
